You are here

  • Home
  • Archive
  • Volume 32, Issue Suppl 2
  • 2022-RA-660-ESGO Characterization of extended treatment benefit from three phase 1 and 3 clinical trials examining patients with folate receptor alpha-positive recurrent ovarian cancer treated with single-agent mirvetuximab soravtansine

Article info

Article menu

Download PDFPDF

Ovarian cancer
2022-RA-660-ESGO Characterization of extended treatment benefit from three phase 1 and 3 clinical trials examining patients with folate receptor alpha-positive recurrent ovarian cancer treated with single-agent mirvetuximab soravtansine
Free

Authors

Citation

Oaknin A, Lorusso D, Oza A, et al
2022-RA-660-ESGO Characterization of extended treatment benefit from three phase 1 and 3 clinical trials examining patients with folate receptor alpha-positive recurrent ovarian cancer treated with single-agent mirvetuximab soravtansine
International Journal of Gynecologic Cancer 2022;32:A251-A252.

Publication history

  • First published October 20, 2022.
Online issue publication 
October 27, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ.